FeesSafety
Pluang+

Telix reports 19% revenue growth in Q3 2026, FDA approves new brain cancer imaging drug Pixclara.

Company Fundamentals
21 Oct 2026, 01:10 WIB
GlobeNewsWire
View Source
Bullish
Telix reports 19% revenue growth in Q3 2026, FDA approves new brain cancer imaging drug Pixclara.

Telix Pharmaceuticals reported a 19% increase in group revenue to US$245 million for Q3 2026, driven by strong demand for its precision medicine products Gozellix and Illuccix. The FDA approved Pixclara for glioma imaging, marking a significant milestone with first commercial doses administered in September. Telix also announced a merger with Isotope Technologies Munich SE to expand its radiopharmaceutical platform and expects FY 2026 revenue to exceed US$1 billion. The company is advancing multiple clinical trials and expanding its manufacturing capabilities to support growth and innovation in cancer diagnostics and therapeutics.

Telix Pharmaceuticals' third quarter 2026 financial performance is presented here alongside Pluang's health sector market data for context. As of Oct 21, 2026 05:01 WIB, out of 150 priced health-sector US stocks on Pluang, 129 rose and 21 fell. Among notable movers, TDOC (Teladoc Health Inc) traded at USD 6.19 with a 1-day gain of 8.03% but showed a Pluang order activity heavily skewed to selling at 99%. In contrast, SYRE (Spyre Therapeutics Inc.) priced at USD 91.40 gained 7.88% with a balanced buy/sell order activity (53% buy). RVMD (Revolution Medicines Inc.) stood at USD 196.49, up 7.87%, with a typical hold time of 5 days on Pluang.

More News

A Race Against Blindness relaunches holiday fundraiser with $125K family prize package including Toyota Sienna and Disney vacation

A Race Against Blindness relaunches holiday fundraiser with $125K family prize package including Toyota Sienna and Disney vacation

A Race Against Blindness has brought back its popular Miles, Magic & Mochas holiday fundraiser, offering supporters a chance to win a prize package valued at $125,000. The package includes a 2026 Toyota Sienna Platinum, a $20,000 Disney vacation awar...

Neutral
52 minutes ago
Shell buys back over 2 million shares as part of its ongoing repurchase program.

Shell buys back over 2 million shares as part of its ongoing repurchase program.

On November 18, 2026, Shell plc repurchased a total of approximately 2.15 million shares across multiple trading venues including the London Stock Exchange and European markets. These shares are being bought back for cancellation under Shell's existi...

Company Fundamentals
Neutral
58 minutes ago
MercadoLibre and Amazon show strong long-term growth despite short-term profit challenges.

MercadoLibre and Amazon show strong long-term growth despite short-term profit challenges.

MercadoLibre and Amazon have both delivered impressive returns over the past decade by continuously growing their customer base, revenue, and profits. MercadoLibre is deliberately sacrificing short-term profits to invest in long-term growth, expandin...

Market News
Bullish
1 hour ago
Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Pfizer will pay its 352nd consecutive quarterly dividend on December 7, 2026, maintaining a strong track record for investors. The company faces challenges like a patent cliff, costly acquisitions, and clinical setbacks that could threaten this strea...

Company Fundamentals
Neutral
1 hour ago
General Mills and Realty Income offer high dividend yields as their stock prices near 52-week lows.

General Mills and Realty Income offer high dividend yields as their stock prices near 52-week lows.

General Mills and Realty Income are trading near their 52-week lows, presenting attractive dividend yields of about 7% and 5.7% respectively. General Mills has a strong dividend history of 127 years and covers its dividend with free cash flow despite...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App